SMT202100030T1 - Piridone ammidi come modulatori di canali del sodio - Google Patents
Piridone ammidi come modulatori di canali del sodioInfo
- Publication number
- SMT202100030T1 SMT202100030T1 SM20210030T SMT202100030T SMT202100030T1 SM T202100030 T1 SMT202100030 T1 SM T202100030T1 SM 20210030 T SM20210030 T SM 20210030T SM T202100030 T SMT202100030 T SM T202100030T SM T202100030 T1 SMT202100030 T1 SM T202100030T1
- Authority
- SM
- San Marino
- Prior art keywords
- modulators
- sodium channels
- pyridone amides
- pyridone
- amides
- Prior art date
Links
- -1 Pyridone amides Chemical class 0.000 title 1
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Ink Jet (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759059P | 2013-01-31 | 2013-01-31 | |
| EP17152492.9A EP3239134B1 (en) | 2013-01-31 | 2014-01-29 | Pyridone amides as modulators of sodium channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202100030T1 true SMT202100030T1 (it) | 2021-03-15 |
Family
ID=50073531
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20210030T SMT202100030T1 (it) | 2013-01-31 | 2014-01-29 | Piridone ammidi come modulatori di canali del sodio |
| SM20170256T SMT201700256T1 (it) | 2013-01-31 | 2014-01-29 | Piridone ammidi come modulatori di canali del sodio |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20170256T SMT201700256T1 (it) | 2013-01-31 | 2014-01-29 | Piridone ammidi come modulatori di canali del sodio |
Country Status (34)
| Country | Link |
|---|---|
| US (6) | US9051270B2 (it) |
| EP (3) | EP2953931B1 (it) |
| JP (4) | JP6389194B2 (it) |
| KR (2) | KR102227592B1 (it) |
| CN (2) | CN105026373B (it) |
| AP (1) | AP2015008633A0 (it) |
| AR (1) | AR094667A1 (it) |
| AU (3) | AU2014212509B2 (it) |
| BR (1) | BR112015018289A2 (it) |
| CA (1) | CA2898866C (it) |
| CL (1) | CL2015002147A1 (it) |
| CY (1) | CY1119163T1 (it) |
| DK (2) | DK3239134T3 (it) |
| ES (2) | ES2857687T3 (it) |
| GE (2) | GEP20217286B (it) |
| HR (2) | HRP20170787T1 (it) |
| HU (2) | HUE033370T2 (it) |
| IL (2) | IL269964B1 (it) |
| LT (2) | LT3239134T (it) |
| MX (2) | MX383688B (it) |
| NZ (2) | NZ710270A (it) |
| PE (2) | PE20151781A1 (it) |
| PH (1) | PH12015501661B1 (it) |
| PL (2) | PL3239134T3 (it) |
| PT (2) | PT2953931T (it) |
| RS (2) | RS56015B1 (it) |
| RU (1) | RU2662223C2 (it) |
| SG (2) | SG11201505953TA (it) |
| SI (2) | SI3239134T1 (it) |
| SM (2) | SMT202100030T1 (it) |
| TW (2) | TWI714967B (it) |
| UA (1) | UA120589C2 (it) |
| UY (1) | UY35288A (it) |
| WO (1) | WO2014120808A1 (it) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933236B2 (en) | 2012-05-22 | 2015-01-13 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
| KR20140105445A (ko) | 2011-10-31 | 2014-09-01 | 제논 파마슈티칼스 인크. | 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도 |
| CA2853439A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| CA2878478A1 (en) | 2012-07-06 | 2014-01-09 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| AR095192A1 (es) | 2013-01-31 | 2015-09-30 | Vertex Pharma | Quinolina y quinazolinamidas como modulares de canales de sodio |
| SMT202100030T1 (it) | 2013-01-31 | 2021-03-15 | Vertex Pharma | Piridone ammidi come modulatori di canali del sodio |
| EP2968280A4 (en) | 2013-03-14 | 2016-08-10 | Genentech Inc | SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| UA119147C2 (uk) | 2013-07-19 | 2019-05-10 | Вертекс Фармасьютікалз Інкорпорейтед | Сульфонаміди як модулятори натрієвих каналів |
| EP3074377B1 (en) | 2013-11-27 | 2018-10-17 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| RS57700B1 (sr) | 2013-12-13 | 2018-12-31 | Vertex Pharma | Prolekovi piridonskih amida korisni kao modulatori kanala za natrijum |
| CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
| BR112017024853A2 (pt) | 2015-05-22 | 2018-08-07 | Genentech Inc | composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto |
| EP3341353A1 (en) | 2015-08-27 | 2018-07-04 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| KR20180067561A (ko) | 2015-09-28 | 2018-06-20 | 제넨테크, 인크. | 치료 화합물 및 그의 사용 방법 |
| US10899732B2 (en) | 2015-11-25 | 2021-01-26 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| AU2017220611A1 (en) | 2016-02-15 | 2018-08-30 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | TAF1 inhibitors for the therapy of cancer |
| WO2017147147A1 (en) * | 2016-02-23 | 2017-08-31 | PixarBio Corporation | Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same |
| WO2017172802A1 (en) | 2016-03-30 | 2017-10-05 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| KR20190078587A (ko) | 2016-10-17 | 2019-07-04 | 제넨테크, 인크. | 치료 화합물 및 그의 사용 방법 |
| US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| EP3625214B1 (en) * | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| TW201920081A (zh) | 2017-07-11 | 2019-06-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑的羧醯胺 |
| EP3752152A1 (en) | 2018-02-12 | 2020-12-23 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| TW202000651A (zh) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | 治療性組成物及其使用方法 |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| US20210387966A1 (en) | 2018-11-02 | 2021-12-16 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| EP3873468A4 (en) | 2018-11-02 | 2022-10-26 | Merck Sharp & Dohme LLC | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS |
| KR20210112336A (ko) * | 2019-01-04 | 2021-09-14 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 6-옥소-1,6-디하이드로피리다진 유도체, 이의 제조 방법, 및 이의 의약적 용도 |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| CN112996774B (zh) * | 2019-01-25 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| TW202102480A (zh) * | 2019-02-20 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | ６－側氧基－１，６－二氫噠嗪類前藥衍生物、其製備方法及其在醫藥上的應用 |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| WO2021018165A1 (zh) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| TW202115038A (zh) * | 2019-08-19 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用 |
| CN112390745B (zh) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
| JP2022548104A (ja) * | 2019-09-12 | 2022-11-16 | オリオン コーポレーション | ピリジン窒素酸化物及びその製造方法と使用 |
| IL293592A (en) | 2019-12-06 | 2022-08-01 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| CN113045487B (zh) * | 2019-12-27 | 2025-01-17 | 明慧医药（上海）有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| AR122628A1 (es) | 2020-06-17 | 2022-09-21 | Merck Sharp & Dohme | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8 |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
| CN114031518B (zh) | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
| US20220380338A1 (en) | 2021-05-07 | 2022-12-01 | Merck Sharp & Dohme Llc | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| CA3221939A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| MX2023014378A (es) | 2021-06-04 | 2023-12-15 | Vertex Pharma | N-(hidroxialquil(hetero)aril)tetrahidrofurano carboxamidas como moduladores de canales de sodio. |
| US20240285596A1 (en) | 2021-06-04 | 2024-08-29 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| US20240294512A1 (en) | 2021-06-04 | 2024-09-05 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| AR126670A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| AR126669A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| WO2023160509A1 (zh) * | 2022-02-25 | 2023-08-31 | 中国科学院上海药物研究所 | 脒类衍生化合物及其制备方法和用途 |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| IL316422A (en) | 2022-04-22 | 2024-12-01 | Vertex Pharma | Heteroaryl compounds for pain treatment |
| CN119677737A (zh) | 2022-04-22 | 2025-03-21 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的杂芳基化合物 |
| EP4511115A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CN119585247A (zh) | 2022-04-25 | 2025-03-07 | 赛特温治疗公司 | 用于治疗疼痛的NaV1.8的双环杂环酰胺类抑制剂 |
| CN116947713A (zh) * | 2022-04-25 | 2023-10-27 | 中国科学院上海药物研究所 | 并环类化合物及其应用 |
| AU2023391870A1 (en) | 2022-12-06 | 2025-06-05 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH598252A5 (it) * | 1974-01-04 | 1978-04-28 | Hoffmann La Roche | |
| GB1447583A (en) * | 1974-02-04 | 1976-08-25 | Ici Ltd | Xanthene derivatives |
| US4086350A (en) * | 1974-11-06 | 1978-04-25 | Smithkline Corporation | Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms |
| GB1543964A (en) * | 1976-04-08 | 1979-04-11 | Ici Ltd | Method of antagonising herbicides on soyabean and cotton |
| US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| JP3285391B2 (ja) * | 1992-09-01 | 2002-05-27 | 日本化学工業株式会社 | ２−フェノキシ安息香酸の製造法 |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| WO2001021652A1 (en) | 1999-09-24 | 2001-03-29 | The Johns Hopkins University School Of Medicine | Methods for identifying an agent that corrects defective protein folding |
| JP2003034671A (ja) | 2001-05-17 | 2003-02-07 | Nippon Nohyaku Co Ltd | ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法 |
| AP1822A (en) | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| JP2007501804A (ja) * | 2003-08-08 | 2007-02-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物 |
| MXPA06002551A (es) * | 2003-09-03 | 2006-06-20 | Pfizer | Compuestos de aril o heteroaril amida. |
| BRPI0513717A (pt) | 2004-07-23 | 2008-05-13 | Pfizer | derivados de piridina |
| US7605174B2 (en) | 2005-06-09 | 2009-10-20 | Vertex Pharmaceuticals Incorporated | Indane derivatives as modulators of ion channels |
| RU2008113836A (ru) | 2005-09-09 | 2009-10-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов |
| WO2007047474A2 (en) | 2005-10-12 | 2007-04-26 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| CN101466665B (zh) * | 2006-04-11 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 适用作电压-门控钠通道抑制剂的组合物 |
| CA2684105C (en) * | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
| US8193194B2 (en) | 2007-05-25 | 2012-06-05 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| AU2008310663A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| CN101855210A (zh) * | 2007-10-11 | 2010-10-06 | 沃泰克斯药物股份有限公司 | 用作电压-门控钠通道抑制剂的酰胺类 |
| US8519137B2 (en) * | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| WO2009058299A1 (en) * | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3 receptor antagonists for treatment of pain |
| BRPI0924059A2 (pt) | 2008-12-23 | 2015-07-07 | Hoffmann La Roche | Didro piridona amidas como moduladores de p2x7 |
| EP2435407B1 (en) * | 2009-05-29 | 2019-12-25 | RaQualia Pharma Inc. | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
| TW201103904A (en) * | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| US8883782B2 (en) * | 2010-03-15 | 2014-11-11 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
| WO2011140425A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| US8999967B2 (en) * | 2010-09-29 | 2015-04-07 | Presidio Pharmaceuticals, Inc. | Tricyclic fused ring inhibitors of hepatitis C |
| SG192248A1 (en) | 2011-02-02 | 2013-09-30 | Vertex Pharma | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
| EP2675810A1 (en) * | 2011-02-15 | 2013-12-25 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
| WO2012112743A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
| JP6088443B2 (ja) | 2011-03-14 | 2017-03-01 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | イオンチャネルのモジュレーターとしてのモルホリン−スピロ環式ピペリジンアミド |
| WO2012122716A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| US20140018398A1 (en) * | 2011-03-29 | 2014-01-16 | Sanofi | Otamixaban formulations with improved stability |
| WO2013021535A1 (ja) | 2011-08-10 | 2013-02-14 | 三菱電機株式会社 | 誘導加熱調理器及びそのプログラム |
| CN102584774B (zh) * | 2011-12-22 | 2014-08-06 | 合肥工业大学 | 一种呫吨酮类衍生物及其用途 |
| RS55814B1 (sr) | 2012-03-06 | 2017-08-31 | Pfizer | Derivati makrociklina za tretman proliferativnih bolesti |
| CN102659628B (zh) * | 2012-04-26 | 2014-07-02 | 四川大学 | 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂 |
| SMT202100030T1 (it) | 2013-01-31 | 2021-03-15 | Vertex Pharma | Piridone ammidi come modulatori di canali del sodio |
| TWI606048B (zh) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
| WO2014120820A1 (en) | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
| AR095192A1 (es) | 2013-01-31 | 2015-09-30 | Vertex Pharma | Quinolina y quinazolinamidas como modulares de canales de sodio |
| UA119147C2 (uk) | 2013-07-19 | 2019-05-10 | Вертекс Фармасьютікалз Інкорпорейтед | Сульфонаміди як модулятори натрієвих каналів |
| RS57700B1 (sr) | 2013-12-13 | 2018-12-31 | Vertex Pharma | Prolekovi piridonskih amida korisni kao modulatori kanala za natrijum |
| TW201920081A (zh) | 2017-07-11 | 2019-06-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑的羧醯胺 |
| EP3752152A1 (en) | 2018-02-12 | 2020-12-23 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
-
2014
- 2014-01-29 SM SM20210030T patent/SMT202100030T1/it unknown
- 2014-01-29 RU RU2015136795A patent/RU2662223C2/ru active
- 2014-01-29 RS RS20170516A patent/RS56015B1/sr unknown
- 2014-01-29 NZ NZ710270A patent/NZ710270A/en unknown
- 2014-01-29 MX MX2015009602A patent/MX383688B/es unknown
- 2014-01-29 TW TW108105717A patent/TWI714967B/zh active
- 2014-01-29 DK DK17152492.9T patent/DK3239134T3/da active
- 2014-01-29 HR HRP20170787TT patent/HRP20170787T1/hr unknown
- 2014-01-29 PE PE2015001572A patent/PE20151781A1/es active IP Right Grant
- 2014-01-29 CA CA2898866A patent/CA2898866C/en active Active
- 2014-01-29 PL PL17152492T patent/PL3239134T3/pl unknown
- 2014-01-29 AR ARP140100281A patent/AR094667A1/es active IP Right Grant
- 2014-01-29 AU AU2014212509A patent/AU2014212509B2/en active Active
- 2014-01-29 HU HUE14704053A patent/HUE033370T2/en unknown
- 2014-01-29 NZ NZ750187A patent/NZ750187A/en unknown
- 2014-01-29 ES ES17152492T patent/ES2857687T3/es active Active
- 2014-01-29 DK DK14704053.9T patent/DK2953931T3/en active
- 2014-01-29 SG SG11201505953TA patent/SG11201505953TA/en unknown
- 2014-01-29 SI SI201431756T patent/SI3239134T1/sl unknown
- 2014-01-29 LT LTEP17152492.9T patent/LT3239134T/lt unknown
- 2014-01-29 US US14/167,759 patent/US9051270B2/en active Active
- 2014-01-29 UY UY0001035288A patent/UY35288A/es active IP Right Grant
- 2014-01-29 SM SM20170256T patent/SMT201700256T1/it unknown
- 2014-01-29 PE PE2019001687A patent/PE20191495A1/es unknown
- 2014-01-29 WO PCT/US2014/013652 patent/WO2014120808A1/en active Application Filing
- 2014-01-29 KR KR1020157023601A patent/KR102227592B1/ko active Active
- 2014-01-29 PL PL14704053T patent/PL2953931T3/pl unknown
- 2014-01-29 SI SI201430220T patent/SI2953931T1/sl unknown
- 2014-01-29 HU HUE17152492A patent/HUE053448T2/hu unknown
- 2014-01-29 PT PT147040539T patent/PT2953931T/pt unknown
- 2014-01-29 AP AP2015008633A patent/AP2015008633A0/xx unknown
- 2014-01-29 KR KR1020217007028A patent/KR102295748B1/ko active Active
- 2014-01-29 IL IL269964A patent/IL269964B1/en unknown
- 2014-01-29 SG SG10201706206PA patent/SG10201706206PA/en unknown
- 2014-01-29 TW TW103103691A patent/TWI655187B/zh active
- 2014-01-29 EP EP14704053.9A patent/EP2953931B1/en active Active
- 2014-01-29 MX MX2021003687A patent/MX2021003687A/es unknown
- 2014-01-29 CN CN201480011392.XA patent/CN105026373B/zh active Active
- 2014-01-29 LT LTEP14704053.9T patent/LT2953931T/lt unknown
- 2014-01-29 UA UAA201508443A patent/UA120589C2/uk unknown
- 2014-01-29 EP EP17152492.9A patent/EP3239134B1/en active Active
- 2014-01-29 GE GEAP201413922A patent/GEP20217286B/en unknown
- 2014-01-29 CN CN201810153601.4A patent/CN108164457B/zh active Active
- 2014-01-29 EP EP20216557.7A patent/EP3865475A1/en active Pending
- 2014-01-29 PT PT171524929T patent/PT3239134T/pt unknown
- 2014-01-29 JP JP2015556109A patent/JP6389194B2/ja active Active
- 2014-01-29 RS RS20210235A patent/RS61503B1/sr unknown
- 2014-01-29 ES ES14704053T patent/ES2626555T3/es active Active
- 2014-01-29 BR BR112015018289A patent/BR112015018289A2/pt not_active Application Discontinuation
- 2014-01-29 GE GEAP201414909A patent/GEP20207177B/en unknown
-
2015
- 2015-04-29 US US14/699,437 patent/US9393235B2/en active Active
- 2015-07-27 PH PH12015501661A patent/PH12015501661B1/en unknown
- 2015-07-28 IL IL24019515A patent/IL240195B/en active IP Right Grant
- 2015-07-31 CL CL2015002147A patent/CL2015002147A1/es unknown
-
2016
- 2016-06-06 US US15/174,896 patent/US9758483B2/en active Active
-
2017
- 2017-05-31 CY CY20171100560T patent/CY1119163T1/el unknown
- 2017-08-03 US US15/667,722 patent/US10087143B2/en active Active
-
2018
- 2018-02-20 JP JP2018027902A patent/JP6741704B2/ja active Active
- 2018-08-09 AU AU2018214105A patent/AU2018214105B9/en active Active
- 2018-08-21 US US16/107,109 patent/US10738009B2/en active Active
-
2019
- 2019-03-25 JP JP2019056505A patent/JP2019089861A/ja not_active Withdrawn
-
2020
- 2020-06-24 US US16/910,965 patent/US11673864B2/en active Active
- 2020-07-02 AU AU2020204425A patent/AU2020204425A1/en not_active Abandoned
- 2020-10-07 JP JP2020169731A patent/JP2021001232A/ja active Pending
-
2021
- 2021-03-01 HR HRP20210349TT patent/HRP20210349T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201706206PA (en) | Pyridone amides as modulators of sodium channels | |
| ZA201603546B (en) | Prodrugs of pyridone amides useful as modulators of sodium channels | |
| SG11201505954RA (en) | Amides as modulators of sodium channels | |
| ZA201600380B (en) | Sulfonamides as modulators of sodium channels | |
| ZA201505326B (en) | Quinoline and quinazoline amides as modulators of sodium channels | |
| ZA201604703B (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| IL240880B (en) | 7 x 2p modulators | |
| SG11201600082VA (en) | Fused piperidine amides as modulators of ion channels |